Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S219-S230
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

The impact of population ageing on the burden of chronic kidney disease
Nicholas C. Chesnaye, Alberto Ortíz, Carmine Zoccali, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 9, pp. 569-585
Closed Access | Times Cited: 35
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes
Muthiah Vaduganathan, Gerasimos Filippatos, Brian Claggett, et al.
Nature Medicine (2024) Vol. 30, Iss. 12, pp. 3758-3764
Open Access | Times Cited: 30
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Yehuda Handelsman, John E. Anderson, George L. Bakris, et al.
Metabolism (2024) Vol. 159, pp. 155931-155931
Open Access | Times Cited: 23
Prevalence of chronic kidney disease among Chinese adults with diabetes: a nationwide population-based cross-sectional study
Weiping Jia, Rong Yu, Limin Wang, et al.
The Lancet Regional Health - Western Pacific (2025) Vol. 55, pp. 101463-101463
Open Access | Times Cited: 2
Revisiting the role of IL-27 in obesity-related metabolic diseases: safeguard or perturbation?
Jinyang An, Dzgoeva Fu, Ximei Chen, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 2
Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a Department of Veterans Affairs quality improvement intervention
Shira Yun, Kathryn M. Hurren, Rob Holleman, et al.
BMC Primary Care (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 2
Unveiling the pathogenesis and therapeutic approaches for diabetic nephropathy: insights from panvascular diseases
Xiaoqian Zhang, Jiale Zhang, Yan Ren, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 15
Diabetes Management in Detention Facilities: A Statement of the American Diabetes Association
Daniel L. Lorber, Nuha A. ElSayed, Raveendhara R. Bannuru, et al.
Diabetes Care (2024) Vol. 47, Iss. 4, pp. 544-555
Open Access | Times Cited: 9
Risk-directed management of chronic kidney disease
Matthew F. Blum, Brendon L. Neuen, Morgan E. Grams
Nature Reviews Nephrology (2025)
Closed Access | Times Cited: 1
Recent advances in understanding the mechanisms by which sodium-glucose co-transporter type 2 inhibitors protect podocytes in diabetic nephropathy
Xinqi Chen, Mingjie Wang, Zhaoli Yan
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
Kosuke Sawami, Atsushi Tanaka, Koichi Node
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
CKD screening for better kidney health: Why? Who? How? When?
Katherine R. Tuttle
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 10, pp. 1537-1539
Closed Access | Times Cited: 7
Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes
Giovanni Antonio Silverii
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S3, pp. 42-54
Closed Access | Times Cited: 7
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Jung‐Im Shin, Yunwen Xu, Alex R. Chang, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 8, pp. 683-693
Closed Access | Times Cited: 6
Unraveling Epigenetic Signatures for Early Detection of Diabetes Nephropathy in Type 2 Diabetes: A Case–Control Investigation
Deeksha Chahar, Gyanendra Kumar Sonkar, Sangeeta Singh, et al.
Biomedical and Biotechnology Research Journal (BBRJ) (2024) Vol. 8, Iss. 1, pp. 108-116
Open Access | Times Cited: 5
A rapid action plan to improve diagnosis and management of lipodystrophy syndromes
Lindsay T. Fourman, Josivan Gomes Lima, Vinaya Simha, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 5
The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review
Liana Iordan, Laura Gaiță, Romulus Timar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7057-7057
Open Access | Times Cited: 5
The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease
M. Vasco, Samuel H. Fantaye, Sapna Raghunathan, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4135-4146
Open Access | Times Cited: 5
Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis
Xia Gu, Shimin Jiang, Yue Yang, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Clinical trial designs of emerging therapies for DKD Clinical trial designs of emerging therapies for diabetic kidney disease (DKD)
Ajay Singh, Youssef M.K. Farag, Zihe Zheng, et al.
Postgraduate Medicine (2024) Vol. 136, Iss. 6, pp. 585-593
Closed Access | Times Cited: 4
CYSTATIN C—A Monitoring Perspective of Chronic Kidney Disease in Patients with Diabetes
Alexandra-Mihaela Visinescu, Emilia Rusu, Andrada Coșoreanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8135-8135
Open Access | Times Cited: 4
Diabetes technology in people with diabetes and advanced chronic kidney disease
Rodolfo J. Galindo, Diana Soliman, Daniel R. Cherñavvsky, et al.
Diabetologia (2024) Vol. 67, Iss. 10, pp. 2129-2142
Open Access | Times Cited: 4
Oral Semaglutide in Type 2 Diabetes: Clinical–Metabolic Outcomes and Quality of Life in Real-World Practice
Paola Pantanetti, Vanessa Ronconi, Marco Sguanci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4752-4752
Open Access | Times Cited: 4
Related factors for kidney disease and high chronic kidney disease progression risk in adult-onset type 1 diabetes mellitus patients from China: a multi-center cross-sectional study
Jun Jiang, Wenjuan Huang, Lei Lan, et al.
Renal Failure (2025) Vol. 47, Iss. 1
Open Access
Meeting People Where They Are: Improving Diabetes Care and Outcomes Through Education and Collaboration
Joshua J. Neumiller
Diabetes Spectrum (2025) Vol. 38, Iss. 1, pp. 115-120
Closed Access
Page 1 - Next Page

Scroll to top